广西地区艾滋病患者临床标本分枝杄菌培养及耐药性分析

doi:10.3969/j.isn.1673-6184.2021.02.005

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (781 KB) HTML ()
Export: BibTeX | EndNote (RIS)

Abstract To investigate the positive rate, distribution and drug resistance of mycobacteria in clinical specimens of AIDS patients, to provide with reference for clinical diagnosis and treatment. Between January 2010 and December 2019, the clinical specimens of AIDS patients in a hospital in Guangxi were cultured with acid-fast bacilli, and the drug resistance test was conducted with more than 8 anti-tuberculosis drugs after isolation and identification. The overall positive rate of acid-fast bacilli culture was 15.68% (2163/13795)，of which the positive rate was high with pus, secretions, various tissue specimens, pleural effusion, and ascites. After species identification, mycobacteria tuberculosis compound group accounted for 77.95% (1442/1850), non-tuberculosis mycobacterium (NTM) accounted for 22.05% (408/1850). The latter accounted for 15.71% - 26.07% over 10 years, with no statistically significant difference between years (χ2=10.442，p>0.05). The total drug resistance rate of acid-fast bacilli was 23.30% (336/1442), the difference over a 10-year period is statistically significant (χ2=18.901, p= 0.026), of which the rate of resistance to isoniazid, rifampicin, streptomycin, ofloxacin, ethambutol, p-aminosalicylic acid, kanamycin was 12.14% (175/336), 10.54% (152/336), 9.29% (134/336), 5.62% (81/336), 3.05% (44/336), 1.80% (26/336), 1.32% (19/336), respectively. The prevalence of MDR-TB, XDR-TB was 5.48% (79/336), 0.28% (4/336), respectively. The study confirmed that the positive rate of mycobacteria isolated from clinical specimens of HIV / AIDS patients is high, of which NTM accounts for a high proportion, and the drug resistance rate of Mycobacterium tuberculosis to commonly used anti-tuberculosis drugs is high. It is suggested that clinical Mycobacterium identification and drug resistance test should be carried out to provide a reliable basis for clinical diagnosis and treatment.

Received: 04 September 2020 Published: 01 January 2021

ZTFEL:	R512.91
	R378.91

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://jmi.fudan.edu.cn/EN/10.3969/j.isn.1673-6184.2021.02.005 OR http://jmi.fudan.edu.cn/EN/Y2021/V16/I2/103

[1]	Chanda-Kapata　P, Kapata N, Klinkenberg E, et　al.The prevalence of HIV among adults with pulmonary TB at a population level in Zambia[J].BMC Infect Dis, 2017, 17(1):236-239
[2]	吴跃, 邓西子, 胡凤玉，等.艾滋病合并非结核分枝杆菌肺病的病原谱、临床特征和耐药情况[J].中华传染病杂志, 2017, 35(3):142-145
[3]	中华医学会感染病学分会艾滋病丙型肝炎学组，中国疾病预防控制中心.中国艾滋病诊疗指南（2018年版），中华内科杂志，2018，57（12）：867-884[J].中华内科杂志, 2018, 57(12):867-884
[4]	中国防痨协会.结病实验室检验规程[J]., 2015, :45-65
[5]	艾滋病毒/艾滋病：https://www.who.int/zh/news-room/fact-sheets/detail/hiv-aids
[6]	World Health Organization.Global tuberculosis report 2019.Geneva:World Health Organization, 2019．
[7]	程勇祥，冯毅.艾滋病与结核病共感染患者肺结核治疗期间死亡的相关因素分析[J].湖南师范大学学报医学版, 2019, 16(2):14-17
[8]	Gao L, Zhou F, Li X, et al.HIVTB co-infection in mainland China:a meta-analysis[J].PLoS One, 2010, 5(5):e10736-
[9]	占魁，陈丰勤，欧书强.例肺结核耐药检测及临床分析[J].江西医药, 2019, 54(8):942-943
[10]	中华人民共和国卫生部.全国结核病耐药性基线调查报告（200-2008[J]., 2010, :-
[11]	中华人民共和国卫生部疾病预防控制局，中国疾病预防控制中心.全国第五次结核病流行病学抽样调查资料汇编[J]., 2011, :-
[12]	Henkle E, Winthrop KL.Nontuberculous mycobacteria infections in immunosuppressed hosts[J].Clin Chest Med, 2015, 36(1):91-99
[13]	张洁，王嫩寒，易俊莉，等.2016～2017年北京地区非结核分枝杆菌菌种分布观察[J].2019，59（12）：34-36.[J].山东医药, 2019, 59(12):34-36
[14]	于海娟，赵梅，王佳月，等.肺结核患者结核杆菌耐药情况及耐多药结核病的危险因素[J].中国感染控制杂志, 2020, 19(1):58-62
[15]	杨新宇，易俊莉，邢青，等，881例疑似耐多药肺结核患者的耐药性分析[J].中国防痨杂志，2018，40（2）：183-188.[J].中国防痨杂志, 2018, 40(2):183-188